MedTrace Logo

Integrating Buprenorphine Into the SFGH AIDS Program

NCT00263458 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2011-09-12

No results posted yet for this study

Summary

The purpose of this study is to assess the feasibility, cost, and effectiveness of a model of care designed to integrate buprenorphine treatment for opioid dependence into the HIV primary care clinics at the UCSF Positive Health Program.

Conditions

  • HIV
  • Buprenorphine
  • Opioid Dependence

Interventions

OTHER

Integrated office-based buprenorphine treatment for opioid dependence in an HIV primary care setting

Eligible opioid-dependent HIV-infected patients are randomly assigned to receive buprenorphine opioid agonist treatment for 12 months either in an integrated HIV primary care setting (intervention group) versus a non-integrated substance use treatment clinic setting (comparison group).

Sponsors & Collaborators

  • San Francisco Department of Public Health

    collaborator OTHER_GOV

  • The New York Academy of Medicine

    collaborator OTHER

  • Health Resources and Services Administration (HRSA)

    collaborator FED

  • University of California, San Francisco

    lead OTHER

Principal Investigators

  • Paula J Lum, MD, MPH · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00263458 on ClinicalTrials.gov